1. Home
  2. COGT vs VET Comparison

COGT vs VET Comparison

Compare COGT & VET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • COGT
  • VET
  • Stock Information
  • Founded
  • COGT 2014
  • VET 1994
  • Country
  • COGT United States
  • VET Canada
  • Employees
  • COGT N/A
  • VET N/A
  • Industry
  • COGT Biotechnology: Pharmaceutical Preparations
  • VET Oil & Gas Production
  • Sector
  • COGT Health Care
  • VET Energy
  • Exchange
  • COGT Nasdaq
  • VET Nasdaq
  • Market Cap
  • COGT 1.1B
  • VET 961.0M
  • IPO Year
  • COGT 2018
  • VET N/A
  • Fundamental
  • Price
  • COGT $12.07
  • VET $8.32
  • Analyst Decision
  • COGT Strong Buy
  • VET
  • Analyst Count
  • COGT 9
  • VET 0
  • Target Price
  • COGT $20.25
  • VET N/A
  • AVG Volume (30 Days)
  • COGT 5.0M
  • VET 926.1K
  • Earning Date
  • COGT 08-05-2025
  • VET 08-07-2025
  • Dividend Yield
  • COGT N/A
  • VET 4.30%
  • EPS Growth
  • COGT N/A
  • VET N/A
  • EPS
  • COGT N/A
  • VET N/A
  • Revenue
  • COGT N/A
  • VET $1,296,504,678.00
  • Revenue This Year
  • COGT N/A
  • VET $39.62
  • Revenue Next Year
  • COGT N/A
  • VET N/A
  • P/E Ratio
  • COGT N/A
  • VET N/A
  • Revenue Growth
  • COGT N/A
  • VET 3.24
  • 52 Week Low
  • COGT $3.72
  • VET $5.14
  • 52 Week High
  • COGT $12.97
  • VET $10.85
  • Technical
  • Relative Strength Index (RSI)
  • COGT 78.82
  • VET 63.00
  • Support Level
  • COGT $11.93
  • VET $7.73
  • Resistance Level
  • COGT $12.79
  • VET $8.02
  • Average True Range (ATR)
  • COGT 0.74
  • VET 0.27
  • MACD
  • COGT 0.03
  • VET 0.05
  • Stochastic Oscillator
  • COGT 76.56
  • VET 83.64

About COGT Cogent Biosciences Inc.

Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.

About VET Vermilion Energy Inc. Common (Canada)

Vermilion Energy Inc is an international oil and gas-producing company. The company engages in full-cycle exploration and production programs that focus on the acquisition, exploration, development, and optimization of producing properties in North America, Europe, and Australia. The majority of Vermilion's revenue is derived from the production and sale of petroleum and natural gas. In each market, the company relies on a host of drilling and well-completion techniques to keep production at attractive levels. Geographically, the company derives majority of its revenue from Canada.

Share on Social Networks: